Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

By J. Edwards, L. Szczepanski, J. Szechiński, A. Filipowicz-Sosnowska, P. Emery, D. Close, R. Stevens, T. Shaw. New England Journal of Medicine, 2004

2,583 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. (2006, methodology): “(%) 52 (35) 11 (9) 27 (14) Insufficient response 46 (31) 8 (6) 16 (8) Adverse events 0 3 (2) 6 (3) All other reasons# 6 (4) 0 5 (3) Completed 24 weeks, no.”
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis (2020, background): “Clinically, combination treatment of either cyclophosphamide or methotrexate with rituximab was shown to be both safe and effective for the treatment of RA without resulting in an increased predisposition to infections (compared to placebo) or adversely modifying immunoglobulin levels in patients [2”
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy (2010, background): “Clinical studies using the anti-CD20 antibody rituximab to deplete mature B cells have provided evidence for the role of B cells in the pathogenesis of rheumatoid arthritis (12), systemic lupus erythematosus (13), and multiple sclerosis (14).”